Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Aptevo Therapeutics reported a 93% clinical benefit rate for its lead candidate mipletamig in combination with venetoclax and azacitidine among 14 evaluable frontline acute myeloid leukemia patients with TP53 mutations, one of the most difficult-to-treat forms of AML. Thirteen of the 14 patients experienced clinical benefit, with 11 achieving CR or CRi (79%) including nine complete remissions — nearly double the published 41% composite remission rate for venetoclax plus azacitidine in this historically poor-responding population.
Key figures
- Drug Name
- mipletamig
- Phase Of Trial
- Phase 1b/2
- Trial name
- RAINIER
- Cr cri rate
- 79%
- Evaluable patients
- 14
- Complete remissions
- 9
- Clinical benefit rate
- 93%
- Dose optimization completion
- year-end 2026
- Regulatory interaction timing
- 1H27
- Patients with clinical benefit
- 13
- Benchmark ven aza remission rate
- 41%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.